Previous 10 | Next 10 |
Merger accelerates transformation to profitability, with estimated annual ized cost synergies of $15M beginning FY 2022 A ytu a dds Neos’ established, multi-brand ADHD portfolio, enhancing Aytu’s footprint in pediatrics and e...
Aytu BioScience (AYTU) and Neos Therapeutics (NEOS) entered into a definitive merger agreement pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction for ~$44.9M.Upon completion of the merger, Neos stockholders will be entitled to ...
Gainers: Greenwich LifeSciences (GLSI) +424%.Xenetic Biosciences (XBIO) +329%.Rocket Pharmaceuticals (RCKT) +79%.MTS Systems (MTSC) +52%.Cypress Environmental Partners (CELP) +46%.Intec Pharma (NTEC) +42%.ZW Data Action Technologies (CNET) +33%.Cardtronics (CATM) +33%.Editas Medicine (ED...
Gainers: Xenetic Biosciences (XBIO) +410%, Greenwich LifeSciences (GLSI) +289%, Rocket Pharmaceuticals (RCKT) +74%, Intec Pharma (NTEC) +64%, ViewRay (VRAY) +14%.Losers: Atossa Therapeutics (ATOS) -39%, Pluristem Therapeutics (PSTI)&...
FinancialBuzz.com News Commentary New York, NY (11/25/2020) – As of earlier this week, the U.S. has reported more than 12.4 million cases and over 257,600 deaths, according to Johns Hopkins University data. Dr. Anthony Fauci, the National Institute of Allergy and Infectious Disea...
Aytu BioScience (AYTU): FQ1 GAAP EPS of -$0.04 beats by $0.02.Revenue of $13.52M (+838.9% Y/Y) beats by $0.19M.Shares -2.91%.Press Release For further details see: Aytu BioScience EPS beats by $0.02, beats on revenue
Q1 Consumer Health revenue reaches an all-time high of $7.8 million Live Conference Call and Webcast at 4:30 PM EST ENGLEWOOD, CO / ACCESSWIRE / November 12, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing no...
Aytu reported Q4 results in October that beat estimates across the board with revenue of $14.86 million, surpassing the $11.24 million revenue analysts were projecting. A careful review of the data supports an estimate of profitability in the upcoming Q1 and an expected increase in sh...
ENGLEWOOD, CO / ACCESSWIRE / November 11, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that management will present a corporate overview at the ...
Live Conference Call and Webcast at 4:30 PM ET ENGLEWOOD, CO / ACCESSWIRE / November 5, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that t...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...